Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib

PURPOSE: Carfilzomib has been approved for use in relapsed and refractory multiple myeloma (RRMM). Cardiac toxicities have been reported with the use of carfilzomib. We aimed to determine the overall incidence and risk of cardiac toxicities in RRMM patients treated with carfilzomib using a meta-anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Fang, Yang, Bo, Wang, Juan, Zhang, Rui, Liu, Jing, Yin, Fenglei, Xu, Weixing, He, Chunyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985801/
https://www.ncbi.nlm.nih.gov/pubmed/29881259
http://dx.doi.org/10.2147/DDDT.S159818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985801/
https://www.ncbi.nlm.nih.gov/pubmed/29881259
http://dx.doi.org/10.2147/DDDT.S159818

Ejemplares similares